106539-36-0 Usage
Description
tert-butyl N-[(2S)-4-hydroxybutan-2-yl]carbamate is a chemical compound with the molecular formula C9H17NO3. It is a derivative of carbamic acid, featuring a tert-butyl group and a 4-hydroxybutan-2-yl group. tert-butyl N-[(2S)-4-hydroxybutan-2-yl]carbamate is known for its reactivity and is commonly used as a building block in the synthesis of various chemical compounds.
Uses
Used in Pharmaceutical Industry:
tert-butyl N-[(2S)-4-hydroxybutan-2-yl]carbamate is used as a building block for the synthesis of allylamines and N-Boc-β-amino acids, which are essential in the development of new pharmaceutical compounds. These synthesized compounds can be utilized in the treatment of various medical conditions, making this carbamate an important component in drug discovery and development.
Used in Chemical Synthesis:
In the field of chemical synthesis, tert-butyl N-[(2S)-4-hydroxybutan-2-yl]carbamate serves as a versatile building block for creating a wide range of chemical compounds. Its unique structure allows for various reactions, enabling the formation of complex molecules with potential applications in different industries, such as agriculture, materials science, and environmental science.
Check Digit Verification of cas no
The CAS Registry Mumber 106539-36-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,6,5,3 and 9 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 106539-36:
(8*1)+(7*0)+(6*6)+(5*5)+(4*3)+(3*9)+(2*3)+(1*6)=120
120 % 10 = 0
So 106539-36-0 is a valid CAS Registry Number.
106539-36-0Relevant articles and documents
APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF
-
Paragraph 00614, (2019/04/09)
Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.
NOVEL COMPOUNDS
-
Page/Page column 50; 51, (2018/04/12)
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, X1, X2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12and R13 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
INHIBITORS OF AKT ACTIVITY
-
Page/Page column 49, (2008/06/13)
Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
